4. A drug manufacturer is making changes to their drug formulation, and they intend to submit this change as a supplement to the FDA. In this process, the manufacturer needs to update various procedures. There is an urgent need to implement this change and submit the data. The changes of procedures have been reviewed by all departments. However, the assigned quality engineer was unable to complete their review on the submission day, and it was signed by the R&D design engineering manager. How should this superseding signature be documented